Medicare drug coverage

Teriparatide: 2027 Medicare Part D coverage

3,835 of 5,495 Part D plans (70%) list teriparatide on their 2027 formulary, down 28 points from 2026. 97% of those require prior authorization, step therapy, or a quantity limit.

License. US government work, Public Domain Mark 1.0.

2027 compared with 2026

Teriparatide is number 183 by total Medicare Part D spending in 2024 ($213 million). Plans that list it most often put it on tier 5. Counts use 10 RxNorm products for this name.

teriparatide Part D coverage, 2026 and 2027
Measure20262027Change
Part D plans in the file5,5185,495-23
Plans that list it5,378 (97%)3,835 (70%)-28 points
Prior authorization (of plans that list it)5,168 (96%)3,599 (94%)-2 points
Step therapy (of plans that list it)0 (0%)0 (0%)no change
Quantity limit (of plans that list it)4,030 (75%)3,362 (88%)+13 points
Any of the three (of plans that list it)5,260 (98%)3,720 (97%)-1 point
Not listed or restricted (of all plans)5,400 (98%)5,380 (98%)no change

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Formulary tier

teriparatide formulary tier, 2026 and 2027
Tier2026 plans2027 plans
Tier 1164 (3%)107 (3%)
Tier 3115 (2%)149 (4%)
Tier 450 (1%)252 (7%)
Tier 55,029 (94%)3,327 (87%)
Tier 620 (0%)0 (0%)

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

Plan by plan, 2026 to 2027

4,380 plan ids are in both files. 144 of them (3%) added prior authorization, step therapy, or a quantity limit for teriparatide, and 1,069 stopped listing it.

teriparatide: plans in both 2026 and 2027
Plan by planPlans
Same plan id in both years4,380
Listed it in 2026, not in 20271,069 (24%)
Listed it in 2027, not in 202634 (1%)
Moved it to a higher tier38 (1%)
Added prior authorization0 (0%)
Added step therapy0 (0%)
Added a quantity limit144 (3%)
Added at least one of the three144 (3%)
Removed at least one of the three19 (0%)
Plan ids new in 20271,115
2026 plan ids not in the 2027 file1,138

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS 2026 Part D formulary file (basic drugs and plan information), as of September 30, 2026. Publisher page

States from most to least restrictive

Share of 2027 Part D plans offered in each state that leave teriparatide off the formulary or list it with prior authorization, step therapy, or a quantity limit. Montana ranks first at 100%, with 100% of its plans using prior authorization or step therapy; Maryland ranks last at 80%. Ties break on the prior authorization or step therapy share.

States from most to least restrictive for teriparatide, 2027
RankState2027 plansNot listed or restrictedPrior auth or step therapyChange from 2026
1Montana27100%100%no change
2Idaho45100%91%no change
3Alaska9100%89%no change
4North Dakota26100%88%no change
5Minnesota63100%87%no change
6Vermont14100%86%no change
7Wyoming13100%85%no change
8Wisconsin97100%85%no change
9New Mexico68100%81%no change
10Kentucky123100%78%no change
11South Dakota30100%77%no change
12Massachusetts92100%76%no change
13New Hampshire25100%76%no change
14Rhode Island29100%76%no change
15Maine52100%75%no change
16Pennsylvania324100%74%no change
17Utah53100%72%no change
18Mississippi105100%71%no change
19South Carolina91100%70%no change
20Louisiana126100%70%no change
21Delaware43100%70%no change
22Oklahoma81100%69%no change
23Arizona148100%69%no change
24New Jersey74100%68%no change
25West Virginia70100%67%no change
26Indiana140100%66%no change
27Texas412100%66%no change
28Florida549100%65%no change
29Arkansas86100%65%no change
30Nebraska51100%65%no change
31North Carolina177100%63%no change
32Tennessee157100%62%no change
33Iowa64100%61%no change
34Illinois133100%59%no change
35New York215100%58%no change
36Kansas84100%57%no change
37Missouri171100%56%no change
38Michigan183100%54%no change
39Connecticut54100%54%no change
40Alabama115100%53%no change
41Ohio17398%62%no change
42Nevada10097%73%-3 points
43Virginia14596%72%no change
44Oregon9296%61%no change
45Georgia15195%67%no change
46Colorado10690%57%+3 points
47Hawaii5088%40%+1 point
48California39788%78%no change
49Washington11486%55%+1 point
50District of Columbia2186%67%-2 points
51Maryland4980%39%-5 points

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

By parent organization

164 parent organizations offer 2027 Part D plans. Humana Inc. has the most, 884, and 100% of them leave teriparatide off or restrict it.

teriparatide coverage by parent organization, 2027
Parent organization2027 plans ↓List itRestrict it (of listing)Not listed or restrictedChange from 2026Plans that added a restriction
Humana Inc.884100%100%100%no change0
UnitedHealth Group, Inc.850100%100%100%no change2
Devoted Health, Inc.7280%none list it100%no change0
CVS Health Corporation6330%none list it100%no change0
Elevance Health, Inc.294100%100%100%no change0
Centene Corporation268100%100%100%no change0
Health Care Service Corporation231100%100%100%no change4
Kaiser Foundation Health Plan, Inc.112100%0%0%no change0
Highmark Health98100%100%100%no change0
SCAN Group85100%100%100%no change54
Alignment Healthcare USA, LLC77100%100%100%no change0
Guidewell Mutual Holding Corporation55100%100%100%no change0
Blue Cross Blue Shield of Michigan Mutual Ins. Co.430%none list it100%no change0
Molina Healthcare, Inc.430%none list it100%no change0
Corewell Health40100%100%100%no change0
Zing Health Consolidator, Inc360%none list it100%no change0
CAPITAL BLUE CROSS35100%100%100%no change0
Medica Holding Company31100%100%100%no change0
UPMC Health System30100%100%100%no change0
Universal Health Services, Inc.290%none list it100%no change0
MHH Healthcare, L.P.2623%100%100%no change0
Independence Health Group, Inc.25100%100%100%no change0
Point32Health, Inc.23100%100%100%no change0
BlueCross BlueShield of Tennessee22100%100%100%no change0
California Physicians' Service22100%100%100%no change0

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Run it in Rivvi

Which 2027 plans near you dropped or restricted teriparatide?

Tier changes and new prior auth, step therapy or quantity limits, plan by plan, before open enrollment.

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Other Teriparatide products

Near it by Part D spending

About this data

A plan here is one Part D plan as the CMS formulary files list it: contract, plan, and segment. That covers Medicare Advantage plans with drug coverage and stand-alone drug plans. A plan lists a drug when its formulary has a row for any RxNorm product of that name. When it has several, the row with the lowest tier is the one counted, and restricted means that row has prior authorization, step therapy, or a quantity limit.

A plan with no row for the drug counts as not listing it. That can be a product the file codes another way, so read a low count as a lookup result, not a coverage decision. A state counts every plan the CMS landscape file offers there. Parent organizations are named as CMS names them. The drug list is the top 200 by total Part D spending.

Source: CMS 2027 Part D formulary file (basic drugs and plan information), as of October 8, 2026. Publisher page

Source: CMS CY2027 landscape file (states and parent organizations), as of September 30, 2026. Publisher page

Source: CMS Medicare Part D Spending by Drug, 2024 data, as of June 25, 2026. Publisher page

Try it on your own data today.

Free to start. Most teams are using it the same day.

Get started for freeSee pricing